Compare Deere & Company (DE) vs Incyte Corporation (INCY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Deere & Company vs Incyte Corporation — how do they compare? Deere & Company trades at $616.11 (market cap $166.81B), while Incyte Corporation trades at $121.35 (market cap $24.54B). The key difference: Deere & Company is far larger — about 6.8× Incyte Corporation's market cap, and Deere & Company pays a 1.05% dividend while Incyte Corporation pays none. Which is the better fit depends on your goals.
| DE | INCY | |
|---|---|---|
Market Cap | $166.81B | $24.54B |
Sector | Industrials | Health |
52-Week High | $662.49 | $129.93 |
52-Week Low | $439.11 | $81.61 |
Enterprise Value | $221.63B | $20.04B |
Dividend Yield | 1.05% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Deere & Company (DE) trades at $609.28, down 1.86% on the day, amid mixed signals. The stock shows a bullish technical trend with strong moving averages, but oscillators are neutral. Recent earnings have consistently beaten expectations, with Q1 2026 EPS of $6.55 surpassing the $5.70 estimate. Revenue declined to $44.67B in 2025, with net income margin at 10.33%. Analyst consensus is a Moderate Buy, with a price target of $669.79, implying potential upside. The company maintains a solid balance sheet with $8.48B in cash, though debt levels remain elevated.
The outlook for DE is cautiously optimistic, driven by earnings beats and analyst confidence, but tempered by revenue declines and agricultural cycle risks. Investment opportunity lies in the valuation gap to the consensus target, while key risks include weak North American demand and margin pressure highlighted in recent industry reports. The stock's performance hinges on upcoming Q3 2026 earnings on August 20, 2026.
INCY trades at $121.55, near its consensus price target of $122.82, with a bullish technical signal and strong recent earnings beats. Revenue grew to $5.14B in 2025, with net income surging to $1.29B, reflecting robust profitability. The company raised its 2026 revenue outlook following strong Q2 results and positive developments like EU approval for Opzelura.
Outlook is positive with solid fundamentals and analyst support, though risks include competitive pressures and reliance on key products. The stock offers growth potential but requires monitoring of execution and market conditions.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Deere & Company
Deere is the world's leading manufacturer of agricultural equipment, producing some of the most recognizable machines in the heavy machinery industry. The company is divided into four reportable segments: production and precision agriculture, small agriculture and turf, construction and forestry, and John Deere Capital. Its products are available through an extensive dealer network, which includes over 1,900 dealer locations in North America and approximately 3,700 locations globally. John Deere Capital provides retail financing for machinery to its customers, in addition to wholesale financing for dealers, which increases the likelihood of Deere product sales.
Read more on DE →About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →
